Healthcare-focused investment firm OrbiMed Asia Partners has led a US$30 million series C round in Zai Lab Ltd., a Shanghai-based innovative biopharmaceutical company.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
